Cargando…
Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489326/ https://www.ncbi.nlm.nih.gov/pubmed/25208608 http://dx.doi.org/10.1111/1471-0528.13070 |
_version_ | 1782379337238970368 |
---|---|
author | Schwarz, T Spaczynski, M Kaufmann, A Wysocki, J Gałaj, A Schulze, K Suryakiran, P Thomas, F Descamps, D |
author_facet | Schwarz, T Spaczynski, M Kaufmann, A Wysocki, J Gałaj, A Schulze, K Suryakiran, P Thomas, F Descamps, D |
author_sort | Schwarz, T |
collection | PubMed |
description | OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged 15–55 years, age-stratified into groups: 15–25, 26–45, and 46–55 years) who received three vaccine doses in the primary study. METHODS: Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME MEASURES: Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1. RESULTS: At 6 years after dose 1, all women were seropositive for anti-HPV–16 and ≥97% were seropositive for anti-HPV–18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV–16 and anti-HPV–18, respectively. In all age groups, GMTs were higher (anti-HPV–16, 9.3–45.1-fold; anti-HPV–18, 4.3–19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81–0.96 (anti-HPV–16) and 0.69–0.84 (anti-HPV–18). Exploratory modelling based on the 6–year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV–18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported. CONCLUSIONS: At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups. |
format | Online Article Text |
id | pubmed-4489326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44893262015-07-07 Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study Schwarz, T Spaczynski, M Kaufmann, A Wysocki, J Gałaj, A Schulze, K Suryakiran, P Thomas, F Descamps, D BJOG Gynaecological Oncology OBJECTIVE: Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN: Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase–III study (NCT00196937). SETTING: Six centres in Germany and Poland. POPULATION: 488 healthy women (aged 15–55 years, age-stratified into groups: 15–25, 26–45, and 46–55 years) who received three vaccine doses in the primary study. METHODS: Immune responses were evaluated in serum and cervicovaginal secretion (CVS) samples 6 years after dose 1. Anti-HPV-16/18 geometric mean titres (GMTs) were measured by enzyme-linked immunosorbent assay (ELISA), and were used to fit the modified power-law and piecewise models, predicting long-term immunogenicity. Serious adverse events (SAEs) were recorded. MAIN OUTCOME MEASURES: Anti-HPV-16/18 seropositivity rates and GMTs 6 years after dose 1. RESULTS: At 6 years after dose 1, all women were seropositive for anti-HPV–16 and ≥97% were seropositive for anti-HPV–18 antibodies. GMTs ranged from 277.7 to 1344.6 EU/ml, and from 97.6 to 438.2 EU/ml, for anti-HPV–16 and anti-HPV–18, respectively. In all age groups, GMTs were higher (anti-HPV–16, 9.3–45.1-fold; anti-HPV–18, 4.3–19.4-fold) than levels associated with natural infection (29.8 EU/ml). A strong correlation between serum and CVS anti-HPV-16/18 levels was observed, with correlation coefficients of 0.81–0.96 (anti-HPV–16) and 0.69–0.84 (anti-HPV–18). Exploratory modelling based on the 6–year data predicted vaccine-induced anti-HPV-16/18 levels above natural infection levels for at least 20 years, except for anti-HPV–18 in the older age group (piecewise model). One vaccine-related and two fatal SAEs were reported. CONCLUSIONS: At 6 years after vaccination, immune responses induced by the HPV-16/18 AS04-adjuvanted vaccine were sustained in all age groups. John Wiley & Sons, Ltd 2015-01 2014-09-11 /pmc/articles/PMC4489326/ /pubmed/25208608 http://dx.doi.org/10.1111/1471-0528.13070 Text en © 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Gynaecological Oncology Schwarz, T Spaczynski, M Kaufmann, A Wysocki, J Gałaj, A Schulze, K Suryakiran, P Thomas, F Descamps, D Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title_full | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title_fullStr | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title_full_unstemmed | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title_short | Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
title_sort | persistence of immune responses to the hpv-16/18 as04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study |
topic | Gynaecological Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489326/ https://www.ncbi.nlm.nih.gov/pubmed/25208608 http://dx.doi.org/10.1111/1471-0528.13070 |
work_keys_str_mv | AT schwarzt persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT spaczynskim persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT kaufmanna persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT wysockij persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT gałaja persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT schulzek persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT suryakiranp persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT thomasf persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy AT descampsd persistenceofimmuneresponsestothehpv1618as04adjuvantedvaccineinwomenaged1555yearsandfirsttimemodellingofantibodyresponsesinmaturewomenresultsfromanopenlabel6yearfollowupstudy |